Our Science and Pipeline

HomeOur Science and Pipeline

Our Science & Pipeline

Introducing Nck blockers

Targeted modulation of TCR activation without immunosuppression
  • Revolutionary first-in-class small molecule therapies
  • Novel MoA effective across multiple diseases
  • Strong safety profile, potential for combination
  • Oral administration and once-daily dosing
  • Strong IP position until 2039

Mechanism of action:
Nck blockers stop autoimmune diseases at the roots source

AX-158 acts by modulation of T-cell activation, not by suppression

AX-158: pipeline in a product
Building an exciting pipeline in key autoimmune indications

Targeted modulation of the T-cell receptor (TCR) activation forms the core of everything we do at Artax Biopharma. We develop medicines that act to specifically block Nck recruitment upon TCR activation, preventing inappropriate activation by self-antigens — and therefore without causing immunosuppression.

Phase 1 results
with AX-158

Completed in 2023

  • Single and multiple doses well tolerated at all dose levels tested
  • Excellent bioavailability with consistent, predictable PK
  • May be dosed independent of food
  • No serious adverse events or related adverse events